2/7
02:07 am
mxct
Medium
Report
1/12
08:27 am
mxct
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
1/12
08:05 am
mxct
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
1/10
01:07 am
mxct
Medium
Report
12/1
09:22 am
mxct
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO [Yahoo! Finance]
Medium
Report
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO [Yahoo! Finance]
12/1
09:00 am
mxct
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Medium
Report
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
11/25
01:54 pm
mxct
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/22
02:11 am
mxct
Neutral
Report
11/22
02:11 am
mxct
Neutral
Report
11/18
01:18 pm
mxct
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MaxCyte (NASDAQ:MXCT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.